SOURCE: ChromoCure, Inc.

March 25, 2010 09:00 ET

ChromoCure to Begin Live Animal Trials for Clinical Therapeutics Research With University Research Programs

RENO, NV--(Marketwire - March 25, 2010) -  ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure announced today an expansion of its Cancer Research initiatives with Live Animal Therapeutics Research collaboration with selected University Cancer Research Programs.

This Collaborative Research Initiative will be a strategic expansion of the Company's "Project Boveri: Find the Cure," adding the ability to monitor hourly chromosome aneuploidy progression. The company's technology and related research opens the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication.

The Company believes its cancer detection and progression measurement capabilities provide unprecedented monitoring and objective measurement of therapeutic research and results.

The Company's focus on cancer research has been validated and further underscored by recent major clinical publications that both validate ChromoCure's chromosomal (aneuploidy) theory of cancer and establish the company's detection approach as the forefront of both cancer detection and research.

The Company's proprietary technology has proven accurate in the measurement of the unique genomic characteristic found in 100% of all cancers and to have an effective accuracy of 100% for all cancers at all stages. ChromoCure's scanner technologies include proprietary designs, processes, and algorithms centered on chromosomal imbalance. They provide the foundation for significant advantages in delivering important results in diagnosis, therapy and cure.

The Company invites University collaboration through its "Project Boveri: Find the Cure" initiative.

The Company will soon announce important additions and changes to its operations and research in the areas of therapeutics and disease eradication.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information